Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.51 |
| ▸ | POLB | P06746 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | SIGMAR1 | Q99720 | 6/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | HRH1 | P35367 | 1/20 | 0.44 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7548883 | 0.90 | KMT2A (0.44) | TDP1POLBKMT2ASIGMAR1ALDH1A1 | |
| SCHEMBL7547422 | 0.83 | KMT2A (0.45) | TDP1POLBKMT2ASIGMAR1ALDH1A1 | |
| SCHEMBL7542200 | 0.80 | POLB (0.49) | TDP1POLBKMT2AALDH1A1LMNA | |
| SCHEMBL7541789 | 0.78 | KMT2A (0.49) | POLBKMT2AALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL7539351 | 0.76 | KMT2A (0.43) | TDP1POLBKMT2ASIGMAR1ALDH1A1 | |
| SCHEMBL17715653 | 0.76 | POLB (0.48) | TDP1POLBKMT2ASIGMAR1ALDH1A1 | |
| SCHEMBL7520663 | 0.75 | KMT2A (0.48) | TDP1POLBKMT2AALDH1A1LMNA | |
| SCHEMBL12174330 | 0.74 | POLB (0.41) | TDP1POLBKMT2ASIGMAR1 | |
| SCHEMBL7571623 | 0.74 | POLB (0.41) | TDP1POLBKMT2ASIGMAR1 | |
| SCHEMBL7539075 | 0.74 | KMT2A (0.43) | KMT2AALDH1A1LMNASMN1; SMN2L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100292203-A1 | HETEROCYCLIC ASPARTYL PROTEASE INHIBITORS | SCHERING CORPORATION | 2010-11-18 | — | — | US | disclosed |
| US-20100292203-A1 | HETEROCYCLIC ASPARTYL PROTEASE INHIBITORS | SCHERING CORPORATION | 2010-11-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100292203-A1 | HETEROCYCLIC ASPARTYL PROTEASE INHIBITORS | CHRM1, CHRM2, PRSS1 | TDP1 534/4885POLB 2893/4885KMT2A 4458/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.